UK

The rollout follows the device’s receipt of both CE mark and UK Conformity Assessed (UKCA) certification, allowing hospitals and healthcare providers in eligible European countries to begin purchasing the system.

The move follows Sanner’s acquisition of Springboard in January 2024 and reflects the company’s goal of building a seamless, end-to-end CDMO platform spanning medical technology, pharmaceuticals, and biotechnology.

The Respiratory Summit 2026, held in London, brought together representatives from the asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, and chronic rhinosinusitis communities for the first time under a shared prevention agenda.

This broader licence gives AviadoBio the flexibility to explore new development pathways and external collaborations while continuing to advance its central nervous system pipeline.

The EMA Committee for Orphan Medicinal Products supported the designation after recognising a strong unmet need in neuroendocrine carcinomas.

Anaphylaxis occurs when the immune system overreacts to a substance it perceives as harmful, triggering symptoms that can rapidly become life-threatening.

The approval allows the company to market the medicine across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway, subject to national pricing, reimbursement, and market-access requirements.

The Hatfield facility, located north of London, will undergo a phased upgrade that will significantly expand its manufacturing, packaging and distribution capabilities.

The acquisition comes as GSK intensifies its shift toward oncology to offset expected revenue pressure from upcoming patent expirations in its HIV franchise.

Researchers tested the therapy through the MATCH clinical trial, which involved 50 patients with advanced liver cirrhosis.